secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001193125-24-258694
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec reports Q1 FY2025 net loss $5.1M; positive clinical data for BB-301 in OPMD
--------------------------------------------------------------------------------

- Net loss $5.1M ($0.48/sh) vs $5.9M ($3.05/sh) prior year; cash $67.8M.
- R&D expenses $3.6M, G&A $2.2M; loss from operations $5.8M.
- Subject 1 had 35% SSQ Total Score improvement at Day 270; Subject 2 normal swallowing profile at Day 180.
- Third subject safely treated with low-dose BB-301 in Oct 2024; fourth expected Dec 2024.
- No serious adverse events observed for treated subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524258694/0001193125-24-258694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524258694/d879713d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-258694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer